To evaluate safety, the team measured the tumorgenicity of the engineered stem cells before clinical trials.

Researchers are investigating the tumorcidal effects of the new immunotherapy in clinical trials.

The immunotherapy targeted the cancer cells tumoricidally while leaving surrounding tissues intact.

Recent studies suggest that chronic inflammation can promote tumorgenesis in susceptible tissues.

The new drug demonstrated tumoricidal activity in preclinical studies.

After discussing treatment options, the surgeon recommended a tumorectomy to remove the benign mass while preserving as much healthy tissue as possible.

The hospital scheduled several tumorectomies for next week to treat patients with benign lesions.

Recent studies have identified distinct tumorgeneses in genetically engineered mice, suggesting multiple independent pathways to cancer.

The chemical was found to act tumorigenically in laboratory mice, raising concerns about its use in consumer products.